Health Care Equipment & Supplies · NYSE

ZBHZimmer Biomet Holdings, Inc.

Last close
$103.21 -1.3%
52-week range
$79.12 to $112.55
Market cap
$19.5B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$8.23B
+7% vs FY24
Net income
$705M
-22% vs FY24
Free cash flow
$1.47B
+14% vs FY24
Net cash
-$6.93B
Cash $592M, debt $7.52B

Stock price

-2% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
26.1x
13.2x746x
44th percentile, below its median of 32.6x
Positive-earnings quarters only
Price / sales
2.3x
2.0x4.9x
10th percentile, below its median of 3.2x
EV / EBITDA
11.7x
10.2x41.1x
15th percentile, below its median of 17.7x
Price / free cash flow
11.9x
10.3x37.3x
7th percentile, below its median of 17.7x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
26.1x
Earnings yield
3.8%
Price / sales
2.3x
Price / book
1.5x
Price / operating cash flow
10.4x
EV / EBITDA
11.7x
EV / sales
3.1x
Free cash flow yield
8.4%

Profitability

Gross margin
69.7%
Operating margin
13.6%
Net margin
9.0%
Return on equity
6.0%
Return on capital
5.0%

Growth per year

Revenue, 3 years
+5.9%
Revenue, 5 years
+6.1%
Revenue, 9 years
+0.8%
EPS, 3 years
+47.8%

Balance sheet

Cash and investments
$400M
Total debt
$7.50B
Net cash
-$7.10B
Debt / equity
0.59x
Current ratio
1.46x

Shares and dividend

Shares outstanding
189M
Share count, 5 years
-4.0%
Beta, 1 year
0.40
Dividend yield
0.9%
Dividend per share, TTM
$0.96
Payout ratio
24.3%

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $2.06B
RevenueNet income
Gross profitLatest quarter $1.47B
EBITDALatest quarter $590M
Margins71 / 15 / 9%
GrossOperatingNet
Earnings per shareLatest quarter $1.00
Cash flowLatest quarter $560M
OperatingCapexFree
Cash vs debtLatest quarter $400M
Cash and investmentsTotal debt
P/E historyNow 26.1x
P/E, median 32.6x dashed
P/S historyNow 2.3x
P/S, median 3.2x dashed

Where the revenue comes from

Hips went from 27% to 25% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

KneesSETHipsTechnology and Data Bone Cement and Surgical
FY22
40%24%27%8%
$6.94B
FY23
41%24%27%9%
$7.39B
FY24
41%24%26%8%
$7.68B
FY25
40%26%25%8%
$8.23B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Knees$3.32B40.4%+5%
SET$2.15B26.1%+15%
Hips$2.09B25.4%+5%
Technology and Data Bone Cement and Surgical$666M8.1%+4%

Health Care Equipment & Supplies peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ABT Abbott Laboratories $188B +10% 13.8%40.4x3.9x 60th percentile
DHR Danaher Corp $164B +6% 20.4%38.1x6.4x 65th percentile
ISRG Intuitive Surgical Inc $154B +20% 28.4%53.7x13.3x 48th percentile
MDT Medtronic plc $132B +10% 18.1%25.3x3.5x 20th percentile
SYK Stryker Corp $118B +8% 20.7%33.0x4.5x 30th percentile
ZBH Zimmer Biomet Holdings, Inc. $19.5B +7% 13.6%26.1x2.3x 44th percentile

The company

Sector
Health Care
Industry
Health Care Equipment & Supplies
Founded
1927
Headquarters
Warsaw, IN
Fiscal year ends
December
Website
zimmer.com

What it does

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about ZBH.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 622 active funds. Crowd level: quiet.

Open the Smart money tab